Trial Profile
A study assessing the steady-state pharmacokinetics and Ctrough of erlotinib over a long time period in patients with pancreatic cancer.
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Pharmacokinetics
- 16 Oct 2016 New trial record